VTM C19 Transit Tube - 50 pk

126.85 126.85000000000001 USD

126.85

Add to Cart
Please note: This item is only available domestically in the US. Additionally, it is made to order and only available to ship on certain days. Please contact your sales representative for more information.

Biomed Diagnostics' VTM-C19 Transit Tube is intended for on-site collection and transport of human clinical specimens containing SARS-CoV-2 and/or (USA only) influenza A virus. Intended to be inoculated with specimens collected with a NP or OP synthetic fiber swab (not included) VTM-C19 has been validated for transport to the lab for analysis with qRT-PCR.


Are you looking for Covid Rapid Antigen tests? 

Contact your sales representative. You'll find their information on your account page.

A premium transport device for use with nucleic acid testing of 

SARS-CoV-2 and Influenza A* specimens

   Principle

  • VTM-C19 Transit Tubes ensures a non-replicating competent status of SARS-CoV-2 (COVID-19) and (USA only) influenza A.

  • Suppresses the growth of other bacteria and fungi that may be present in clinical samples from the human respiratory system

   Convenience

  • Safe transport and preservation of the specimen

  • Compatible with approved nucleic acid extraction and qRT-PCR tests

Storage

The VTM-C19 Transit Tube is based on the CDC formulation which has a shelf-life of twelve-months when stored at either refrigerated or room temperature (2-25°C).

Regulatory Information:

For In Vitro Diagnostic Use. Not available in all countries; please inquire. 

CE IVD marked for use with SARS-CoV-2 testing. The VTM-C19 Transit Tube is available for use in the USA under the FDA guidance “Enforcement Policy for Viral Transport Media During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency” (July 2020). The VTM-C19 Transit Tube has completed the Notification process. 

* The VTM-C19 Transit Tube is available for use in the USA with FDA-cleared molecular influenza tests as described in the FDA guidance “Enforcement Policy for Modifications to FDA-Cleared Molecular Influenza and RSV Tests During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency” (October 2020).